Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.

Abstract:

:We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-alone' patients, we re-categorized 216 patients in keeping with the NIH criteria. Twenty patients were reclassified as having acute GVHD and 196 patients as having cGVHD (170 'classic chronic' (Cl-Ch) and 26 'overlap chronic' (Ov-Ch)). The 5-year GVHD-specific survival (GSS) was significantly different between the two cGVHD subtypes, specifically 87.3% for Cl-Ch vs 70.2% for Ov-Ch (P=0.006). The NIH severity criteria were effective in expecting 5-year GSS rates at both the onset (93.5, 81.3 and 79.7% (P=0.047)) and peak intensity of the disease (100, 89.7 and 78.7% (P=0.004) for the mild, moderate and severe grade, respectively). Multivariate analysis showed that NIH severity criteria were independently significant prognostic factors for GSS (mild vs moderate, HR 4.35, P=0.036; mild vs severe, HR 5.25, P=0.020). Our results support the role of the NIH criteria in classifying cGVHD and in assessing the severity of the disease to predict patient prognosis of cGVHD.

journal_name

Bone Marrow Transplant

authors

Kim DY,Lee JH,Lee JH,Kim SH,Lim SN,Kim SD,Choi Y,Lee YS,Kang YA,Kang SI,Seol M,Ryu SG,Lee KH

doi

10.1038/bmt.2009.320

subject

Has Abstract

pub_date

2010-07-01 00:00:00

pages

1174-80

issue

7

eissn

0268-3369

issn

1476-5365

pii

bmt2009320

journal_volume

45

pub_type

杂志文章
  • Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.

    abstract::Epidermal growth factor (EGF) is a recently described biomarker of acute GvHD (aGvHD). Whether low plasma EGF prior to hematopoietic cell transplantation (HCT) predisposes to the development of aGvHD, or whether EGF levels fall because of severe aGvHD, is unknown. To evaluate this, we tested plasma samples collected a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2017.89

    authors: Holtan SG,Newell LF,Cutler C,Verneris MR,DeFor TE,Wu J,Howard A,MacMillan ML,Antin JH,Blazar BR,Weisdorf DJ,Panoskaltsis-Mortari A

    更新日期:2017-09-01 00:00:00

  • Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens.

    abstract::We previously reported a 25% incidence of serious graft-versus-host disease (GVHD) (that is, acute or chronic GVHD that caused death, lengthy hospitalization or disability, or resulted in recurrent major infections) among 171 hematopoietic cell transplantation (HCT) recipients after nonmyeloablative (NMA) regimen. Her...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705987

    authors: Sala-Torra O,Martin PJ,Storer B,Traina F,Sorror ML,Storb R,Sandmaier BM,Flowers ME

    更新日期:2008-05-01 00:00:00

  • Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.

    abstract::The use of mobilized peripheral blood (PB) stem cells for autologous transplantation initially generated much enthusiasm because of enhanced engraftment in comparison to marrow stem cells and avoidance of general anesthesia for the donor. Its application to the allogeneic setting seemed inevitable. For obvious ethical...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1702464

    authors: Gyger M,Stuart RK,Perreault C

    更新日期:2000-07-01 00:00:00

  • Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.

    abstract:SUMMARY:High-dose busulfan is an important component of myeloablative regimens. Variable drug exposure may occur following oral administration. Therefore, the use of intravenous busulfan has been advocated. Previous work has suggested a cumulative dosage of 16 mg/kg for haematopoietic transplantation in children less t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704209

    authors: Dalle JH,Wall D,Theoret Y,Duval M,Shaw L,Larocque D,Taylor C,Gardiner J,Vachon MF,Champagne MA

    更新日期:2003-10-01 00:00:00

  • AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?

    abstract::Allogeneic hematopoietic stem cell transplantation (alloHSCT) has become a well-established treatment option for many patients suffering from malignant and non-malignant diseases. In the past decade, high-resolution HLA-typing, remission surveillance, pre-emptive immune intervention, and standardisation in supportive ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/s41409-018-0341-z

    authors: Bakhtiar S,Salzmann-Manrique E,Hutter M,Krenn T,Duerken M,Faber J,Reinhard H,Kreyenberg H,Huenecke S,Cappel C,Bremm M,Pfirrmann V,Merker M,Barnbrock A,Schöning S,Willasch AM,Rettinger E,Soerensen J,Klingebiel TE,Jar

    更新日期:2019-05-01 00:00:00

  • Gut protection by palifermin during autologous haematopoietic SCT.

    abstract::Conditioning therapy in connection with haematopoietic SCT (HSCT) induces a disruption of the intestinal barrier function facilitating the permeation of bacteria and endotoxin through the bowel wall with subsequent increased risk of septicaemia and a worsening of GVHD in the allogeneic setting. Palifermin (recombinant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.388

    authors: Johansson JE,Hasséus B,Johansson P,Eklöf C,Ohman D,Stockelberg D

    更新日期:2009-05-01 00:00:00

  • Mobilization of peripheral blood progenitor cells by high-dose Ara C, VP-16 and recombinant human granulocyte colony-stimulating factor: factors affecting progenitor cell yields.

    abstract::Forty seven patients with hematological malignancies were treated with high doses of cytosine arabinoside (Ara C; 12 g/m2) and etoposide (VP-16), followed by recombinant human granulocyte colony-stimulating factor (rhG-CSF; 50 micrograms/m2). Peripheral blood progenitor cells (PBPC) were collected during rapid leukocy...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Shimazaki C,Yamagata N,Tatsumi T,Hirata T,Oku N,Ashihara E,Goto H,Inaba T,Fujita N,Haruyama H

    更新日期:1995-05-01 00:00:00

  • GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression.

    abstract::To determine the effect of growth factor mobilization on the expression of adhesion molecules, we compared CD34+ progenitor cell (PC) populations from steady-state bone marrow (BM) with granulocyte-macrophage colony-stimulating factor (GM-CSF)-mobilized apheresis products (peripheral blood stem cell (PSC)) using flow ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700814

    authors: Watanabe T,Dave B,Heimann DG,Lethaby E,Kessinger A,Talmadge JE

    更新日期:1997-06-01 00:00:00

  • Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells.

    abstract::Among the drugs used in conditioning regimens for stem cell transplantation, high-dose melphalan (HDM) plays an important role for both its strong myeloablative effect and for its favourable dose-response ratio. Here we report five cases of high frequency atrial fibrillation (AF) developing after HDM. Duration of the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701217

    authors: Olivieri A,Corvatta L,Montanari M,Brunori M,Offidani M,Ferretti GF,Centanni M,Leoni P

    更新日期:1998-05-01 00:00:00

  • Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.

    abstract::Receipt of hematopoietic cell transplantation (HCT) can improve overall survival in older patients with intermediate or high-risk acute myeloid leukemia (AML); however, utilization of HCT is poor. It is important to understand the factors that affect the receipt of HCT in a real-world setting among the older patients....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0164-y

    authors: Bhatt VR,Chen B,Gyawali B,Lee SJ

    更新日期:2018-10-01 00:00:00

  • Psychosocial adaptation of patients and families following bone marrow transplantation: a prospective, longitudinal study.

    abstract::Using a prospective, repeated measures design, this study investigated the psychosocial functioning of patients and a close relative pre- and post-allogeneic and autologous bone marrow transplantation (BMT). All patients (n = 28) undergoing BMT in a 1 year period, and their relatives, were interviewed 1 week pre-trans...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701443

    authors: Keogh F,O'Riordan J,McNamara C,Duggan C,McCann SR

    更新日期:1998-11-01 00:00:00

  • Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT.

    abstract::In this cross-sectional study, we compared the quality of life (QOL) in transfusion-dependent thalassemic patients who survived matched sibling hematopoietic SCT (HSCT, n=24) with patients treated conventionally with transfusion and iron chelation (n=74). WHOQOL-BREF(HK) and PedsQL questionnaires were administered to ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2008.165

    authors: Cheuk DK,Mok AS,Lee AC,Chiang AK,Ha SY,Lau YL,Chan GC

    更新日期:2008-09-01 00:00:00

  • Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT.

    abstract::CTLA-4 is a negative regulator of activated T cells and the association of CTLA-4 polymorphisms with autoimmune diseases and transplant outcome has been reported. We evaluated the effect of donor CTLA-4 polymorphisms on outcome after allogeneic hematopoietic SCT (HSCT). We analyzed 147 Japanese HLA-matched sibling rec...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.319

    authors: Murase M,Nishida T,Onizuka M,Inamoto Y,Sugimoto K,Imahashi N,Murata M,Miyamura K,Kodera Y,Inoko H,Naoe T

    更新日期:2011-11-01 00:00:00

  • Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors.

    abstract::We have evaluated the efficacy of administering recombinant human erythropoietin (rh-Epo) to 11 healthy bone marrow donors weighing less than 30 kg. Three weeks before harvesting, the donors received 100 units/kg/day rh-Epo subcutaneously and oral iron supplementation (2.5 mg/kg twice daily). Six children with hematoc...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701310

    authors: Martínez AM,Sastre A,Muñoz A,Badell I,Maldonado MS,Cubells J

    更新日期:1998-07-01 00:00:00

  • Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.

    abstract::Cyclosporin A (CsA) has been used most widely as an immunosuppressive agent for preventing graft-versus-host disease (GVHD). To explore the risk factors including CsA blood levels for grades II-IV acute GVHD, we retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705834

    authors: Izumi N,Furukawa T,Sato N,Okazuka K,Tsukada N,Abe T,Yano T,Kurasaki T,Masuko M,Toba K,Takahashi M,Aizawa Y

    更新日期:2007-11-01 00:00:00

  • Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.

    abstract::In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b in...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lo Coco F,Mandelli F,Diverio D,Alimena G,De Fabritiis P,Meloni G,Cedrone M,Frontani M,Guerrasio A,Saglio G

    更新日期:1990-10-01 00:00:00

  • Serial intestinal endoscopic examinations of patients with persistent diarrhea after allo-SCT.

    abstract::Gastrointestinal (GI) GVHD after allo-SCT is diagnosed on the basis of symptoms and findings in endoscopic mucosal biopsy specimens. However, GI symptoms often persist despite treatment and whether a second endoscopy may be helpful in determining the most suitable therapy is not established. We identified 31 patients ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.143

    authors: Martínez C,Rosales M,Calvo X,Cuatrecasas M,Rodriguez-Carunchio L,Llach J,Fernández-Avilés F,Rosiñol L,Rovira M,Carreras E,Urbano-Ispízua A

    更新日期:2012-05-01 00:00:00

  • Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation.

    abstract::Ninety-eight patients with homozygous-beta thalassemia who had undergone allogeneic bone marrow transplantation (BMT) between May 1990 and March 1992 were tested for hepatitis C antibodies (anti-HCV) before and after BMT. Anti-HCV positivity was detected in 50 of the 98 patients (51%) before BMT. Seroconversion was de...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Erer B,Angelucci E,Lucarelli G,Giardini C,Baronciani D,Galimberti M,Polchi P,Amadei G,Battistini L,Paolucci S

    更新日期:1994-09-01 00:00:00

  • Bone marrow transplantation from unrelated donors: the Italian experience. GITMO, AIEOP and IBMDR.

    abstract::We report on 24 patients with leukemia (19 pts), congenital disorders (4 pts) or severe aplastic anemia (1 pt) who received bone marrow transplantation from unrelated volunteer donors in 8 Italian Institutions. All the donor/recipient pairs were serologically HLA-A,B,DR matched; MLR was non reactive in 21 out of 24 ca...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lanino E,Lamparelli T,Dini G,Alessandrino EP,Aversa F,Calori E,Medugno D,Garbarino L,Locatelli F,Marenco P

    更新日期:1993-01-01 00:00:00

  • Osteopetrosis: a single centre experience of stem cell tranisplantation and prenatal diagnosis.

    abstract::Malignant osteopetrosis (MOP) is an autosomal recessive disease in which osteoclast dysfunction results in excessive bone deposition and early infant death. Thirteen children suffering from MOP from four related families all belonging to one Bedouin tribe, were studied. The disease was diagnosed as early as at a few d...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702743

    authors: Kapelushnik J,Shalev C,Yaniv I,Aker M,Carmi R,Cohen Z,Mozer A,Schulman C,Stein G,Or R

    更新日期:2001-01-01 00:00:00

  • Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders.

    abstract::Post-transplant lymphoproliferative disorders (PTLD) are morphologically/clinically heterogeneous. The main goal of this study was to define the histogenesis of PTLD (B-cell phenotype, EBV-related) in seven pediatric patients after allogeneic T-cell-depleted bone marrow transplantation. Immunohistochemical stains usin...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704395

    authors: Abed N,Casper JT,Camitta BM,Margolis D,Trost B,Orentas R,Chang CC

    更新日期:2004-02-01 00:00:00

  • Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.

    abstract::Recommendations on indications for allogeneic haematopoietic SCT have been presented, but transplantation techniques remain poorly standardized. Pre-transplant risk factors are well defined, and reported outcomes vary markedly among patients with similar risk characteristics. It would be of importance to know the impa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.45

    authors: Ruutu T,van Biezen A,Hertenstein B,Henseler A,Garderet L,Passweg J,Mohty M,Sureda A,Niederwieser D,Gratwohl A,de Witte T

    更新日期:2012-11-01 00:00:00

  • Irradiated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice.

    abstract::Umbilical cord blood (UCB) is a readily available source of hematopoietic stem cells for transplantation. UCB hematopoietic SCT for average- and large-sized patients is often limited by the number of cells available in a single unit. To address this limitation, we performed experiments to determine if adjunctive thera...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.69

    authors: Budak-Alpdogan T,Jeganathan G,Lee KC,Mrowiec ZR,Medina DJ,Todd D,Moore D,Bertino JR,Strair R

    更新日期:2012-12-01 00:00:00

  • Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.

    abstract::Multiple myeloma (MM) is characterized by the expansion of tumor plasma cells in bone marrow (BM), but neoplastic cells have been consistently detected in peripheral blood (PB). Peripheral blood progenitor cell (PBPC) collections have been widely used to support high-dose therapy for MM patients. A flow cytometric tec...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702085

    authors: Boccadoro M,Omedé P,Dominietto A,Palumbo A,Bringhen S,Giaretta F,Ortolano B,Triolo S,Pileri A

    更新日期:2000-01-01 00:00:00

  • Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005.

    abstract::Over more than three decades, The Anthony Nolan Trust (ANT) has provided an unrelated donor (UD) for over 4000 children and adults lacking a suitable family member donor, and has remained at the forefront of developments in haematopoietic stem cell transplantation (HSCT) and bone marrow register management. These thre...

    journal_title:Bone marrow transplantation

    pub_type:

    doi:10.1038/sj.bmt.1705365

    authors: Duarte RF,Pamphilon D,Cornish J,Shaw BE,Samson D,Craddock C,Marks D,Mufti GJ,Powles RL,Apperley JF,Madrigal JA,Goldman JM

    更新日期:2006-05-01 00:00:00

  • Avoiding hepatic veno-occlusive disease: what do we know and where are we going?

    abstract::Hepatic venocclusive disease (VOD) is a common toxicity associated with myeloablative chemotherapy or chemoradiotherapy used to prepare patients for stem cell transplantation. A sizable proportion of patients who develop VOD die. It is clear that injury to endothelial cells and hepatocytes in zone 3 of the liver acinu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703014

    authors: Bearman SI

    更新日期:2001-06-01 00:00:00

  • Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.

    abstract::Knowledge of the vital role of adenosine deaminase in lymphatic tissues has led to the development of enzyme inhibitors for treatment of lymphoid neoplasms. Deoxycoformycin is a potent ADA inhibitor and has been shown to be active in acute lymphoblastic leukemia at high doses but associated with unpredictable toxicity...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Ho AD,Thaler J,Willemze R,Lauria F,Derossi G,Kuse R,Stryckmans P,Blanc CM,Cataldo F,McVie G

    更新日期:1989-01-01 00:00:00

  • Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source.

    abstract::Donor cell-derived leukemia (DCL) is a rare complication of SCT. Here, we present a case of DCL following cord blood transplantation (CBT) and review the clinical features of previously reported DCL. To our knowledge, this is the first report comparing clinical characteristics of DCL from the standpoint of the transpl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2013.127

    authors: Shiozaki H,Yoshinaga K,Kondo T,Imai Y,Shiseki M,Mori N,Teramura M,Motoji T

    更新日期:2014-01-01 00:00:00

  • Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.

    abstract::We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2009.316

    authors: Kimura S,Oshima K,Okuda S,Sato K,Sato M,Terasako K,Nakasone H,Kako S,Yamazaki R,Tanaka Y,Tanihara A,Higuchi T,Nishida J,Kanda Y

    更新日期:2010-06-01 00:00:00

  • Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.

    abstract::A nonmyeloablative conditioning regimen consisting of fludarabine (FLU) and 2 Gy TBI has been used extensively and with substantial engraftment success without promoting excessive nonrelapse mortality in medically infirm patients requiring hematopoietic cell transplantation. In this paper, we studied this same low-tox...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2010.154

    authors: Thakar MS,Kurre P,Storb R,Kletzel M,Frangoul H,Pulsipher MA,Leisenring W,Flowers ME,Sandmaier BM,Woolfrey A,Kiem HP

    更新日期:2011-04-01 00:00:00